Venneri Annalena, Shanks Michael F, Staff Roger T, Pestell Simon J, Forbes Katrina E, Gemmell Howard G, Murray Alison D
Department of Psychology, University of Aberdeen, UK.
Neuroreport. 2002 Jan 21;13(1):83-7. doi: 10.1097/00001756-200201210-00020.
Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECTat baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain.
27名轻度阿尔茨海默病患者被纳入一项关于卡巴拉汀的前瞻性开放标签对照研究。评估包括一系列神经精神和行为测量指标，以及在基线、3个月和6个月时使用锝-99m六甲基丙烯胺肟单光子发射计算机断层扫描（HMPAO SPECT）测量的局部脑血流（rCBF）。在12名接受治疗的患者中观察到额叶、顶叶和颞叶脑血流显著增加，同时心理测量指标有所改善。在4名无反应患者和11名未治疗患者中观察到rCBF和认知表现降低的模式。结果表明，接受胆碱酯酶抑制剂治疗的患者临床和认知状态的改变与rCBF的变化平行。重复成像的纵向评估提供了一种更好地理解胆碱酯酶抑制对阿尔茨海默病大脑影响的方法。
